Skip to main content

Thyroid Follicular Carcinoma with Iodine-Avid Bone Metastases Showing Mild Uptake on Both 18F-FDG and 68Ga-DOTATOC PET/CT

  • Chapter
  • First Online:
Thyroid and Parathyroid Diseases

Abstract

Differentiated thyroid carcinoma (DTC) is usually characterized by good prognosis. Radioiodine scan is the first-line diagnostic tool to detect the metastatic disease. In patients with high Tg levels suggesting metastatic disease when radioiodine scan is negative, 18F-fluorodeoxyglucose positron emission tomography/computerized tomography (FDG PET/CT) is reported to be effective in defining the metastatic foci. Another imaging modality is somatostatin receptor imaging with PET/CT which can be used especially when 18F-FDG PET/CT is nondiagnostic. Peptide receptor radionuclide therapy with β-emitting radionuclides may be considered when somatostatin positivity is defined in metastatic lesions. In this case report, a patient with DTC having radioiodine-positive bone metastases showing mild uptake in 18F-FDG PET/CT and 68Ga-DOTATOC PET/CT is presented.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ito S, Kato K, Ikeda M, Iwano S, Makino N, Tadokoro M, et al. Comparison of 18F-FDG PET and bone scintigraphy in detection of bone metastases of thyroid cancer. J Nucl Med. 2007;48:889–95.

    Article  CAS  Google Scholar 

  2. Nagamachi S, Wakamatsu H, Kiyohara S, Nishii R, Mizutani Y, Fujita S, et al. Comparison of diagnostic and prognostic capabilities of 18F-FDG-PET/CT, 131I-scintigraphy, and diffusion-weighted magnetic resonance imaging for postoperative thyroid cancer. Jpn J Radiol. 2011;29:413–22.

    Article  Google Scholar 

  3. Qiu ZL, Xue HL, Song HJ, Luo QY. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer. Nucl Med Commun. 2012;33:1232–42.

    Article  CAS  Google Scholar 

  4. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133.

    Article  Google Scholar 

  5. Weidinger T, Putzer D, Von Guggenberg E, Dobrozemsky G, Nilica B, Kendler D, et al. Multiparametric PET imaging in thyroid malignancy characterizing tumour heterogeneity: somatostatin receptors and glucose metabolism. Eur J Nucl Med Mol Imaging. 2015;42:1995–2001.

    Article  Google Scholar 

  6. Nockel P, Millo C, Keutgen X, Klubo-Gwiezdzinska J, Shell J, Patel D, et al. Rate and clinical significance of incidental thyroid uptake as detected by Gallium-68 DOTATATE positron emission tomography/computed tomography. Thyroid. 2016;26:831–5.

    Article  CAS  Google Scholar 

  7. Ocak M, Demirci E, Kabasakal L, Aygun A, Tutar RO, Araman A, et al. Evaluation and comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-NOC PET/CT imaging in well-differentiated thyroid cancer. Nucl Med Commun. 2013;34:1084–9.

    Article  CAS  Google Scholar 

  8. Middendorp M, Selkinski I, Happel C, Kranert WT, Grünwald F. Comparison of positron emission tomography with [(18)F]FDG and [(68)Ga]DOTATOC in recurrent differentiated thyroid cancer: preliminary data. Q J Nucl Med Mol Imaging. 2010;54:76–83.

    CAS  PubMed  Google Scholar 

  9. Jois B, Asopa R, Basu S. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin a level-positive neuroendocrine differentiation. Clin Nucl Med. 2014;3:505–10.

    Article  Google Scholar 

  10. Lapa C, Werner RA, Schmid JS, Papp L, Zsótér N, Biko J, et al. Prognostic value of positron emission tomography-assessed tumor heterogeneity in patients with thyroid cancer undergoing treatment with radiopeptide therapy. Nucl Med Biol. 2015;42:349–54.

    Article  CAS  Google Scholar 

  11. Binse I, Poeppel TD, Ruhlmann M, Ezziddin S, Görges R, Sabet A, et al. 68Ga-DOTATOC PET/CT in patients with iodine- and 18F-FDG-negative differentiated thyroid carcinoma and elevated serum thyroglobulin. J Nucl Med. 2016;57:1512–7.

    Article  CAS  Google Scholar 

  12. Versari A, Sollini M, Frasoldati A, Fraternali A, Filice A, Froio A, et al. Differentiated thyroid cancer: a new perspective with radiolabeled somatostatin analogues for imaging and treatment of patients. Thyroid. 2014;24:715–26.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Çermik, T.F., Ergül, N. (2019). Thyroid Follicular Carcinoma with Iodine-Avid Bone Metastases Showing Mild Uptake on Both 18F-FDG and 68Ga-DOTATOC PET/CT. In: Özülker, T., Adaş, M., Günay, S. (eds) Thyroid and Parathyroid Diseases. Springer, Cham. https://doi.org/10.1007/978-3-319-78476-2_55

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-78476-2_55

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-78475-5

  • Online ISBN: 978-3-319-78476-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics